Examination of postincarceration fatal overdoses after addiction treatment medications in correctional system

February 14, 2018

Bottom Line: There were fewer postincarceration deaths from overdose among recently released inmates after a program was started to provide medications for addiction treatment (including methadone, buprenorphine or naltrexone) in a state correctional system.

Why The Research Is Interesting: Most correctional facilities in the United States don't initiate or continue to provide medications for addiction treatment to inmates. Rates of opioid overdose are higher immediately after inmates are released from incarceration. A program for screening and treatment with medications for addiction treatment was launched in the Rhode Island Department of Corrections (RIDOC) in 2016. Inmates entering RIDOC who were receiving medications for addiction treatment maintained their medication regimens and community centers helped to link inmates with medication and supportive care after they were released. This research letter is a preliminary examination of that program.

Who and When: All unintentional deaths from overdose in Rhode Island from January to June in 2016 and 2017; individuals who died within 12 months of release from RIDOC

What (Study Measures): Compared the proportion of people who died from accidental overdose who were incarcerated in 2017 with those incarcerated in 2016 since individual-level data of enrollment in the medications for addiction treatment program were unavailable.

How (Study Design): This was an observational study. Researchers were not intervening for purposes of the study and therefore cannot control all the natural differences that could explain the study findings.

Authors: Traci C. Green, Ph.D., M.Sc., of the Warren Alpert Medical School of Brown University, Providence, Rhode Island, and coauthors

Results: 26 of 179 individuals (14.5 percent) who died of an overdose in the first six months of 2016 were recently incarcerated compared with 9 of 157 (5.7 percent) in the same period in 2017, a 60.5 percent reduction in mortality.

Study Limitations: A small study sample and a lack of data on medications for addiction treatment after an inmate's release were some of the limitations of the study that warrant additional analyses.

Study Conclusions: Identifying and treating opioid use disorder in criminal justice settings, along with linking inmates to medication and supportive care after they are released, is a promising strategy to address high rates of overdose and opioid use disorder.

For more details and to read the full study, please visit the For The Media website.

(doi:10.1001/ jamapsychiatry.2017.4614)

Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc. Want to embed a link to this study in your story? Link will be live at the embargo time: http://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2017.4614

JAMA Psychiatry

Related Medication Articles from Brightsurf:

New medication may treat underlying causes of hypertrophic cardiomyopathy
Mavacamten, a new investigational cardiac medication, may improve heart function for people with thickened heart muscle leading to obstructed blood flow through the heart, a condition known as obstructive hypertrophic cardiomyopathy.

Therapy plus medication better than medication alone in bipolar disorder
A review of 39 randomized clinical trials by scientists from UCLA and their colleagues from other institutions has found that combining the use medication with psychoeducational therapy is more effective at preventing a recurrence of illness in people with bipolar disorder than medication alone.

Kids diagnosed with ADHD often don't take medication regularly
Children diagnosed with ADHD inconsistently take their prescribed medication, going without treatment 40 per cent of the time, a new study has found.

Long-term medication for schizophrenia is safe
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.

Which is more effective for treating PTSD: Medication, or psychotherapy?
A systematic review and meta-analysis led by Jeffrey Sonis, MD, MPH, of the University of North Carolina School of Medicine, finds there is insufficient evidence at present to answer that question.

ADHD medication: How much is too much for a hyperactive child?
When children with ADHD don't respond well to Methylphenidate (MPH, also known as Ritalin) doctors often increase the dose.

Pain medication use by children after common surgeries
About 400 caregivers reported pain medication use by children after common surgeries such as hernia, elbow fracture, appendectomy or adenoid removal in this study.

Bringing cancer medication safely to its destination
Treating cancer more selectively and more effectively -- this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU).

Bullying linked to student's pain medication use
In a school-based survey study of all students in grades 6, 8, and 10 in Iceland, the use of pain medications was significantly higher among bullied students even when controlling for the amount of pain they felt, as well as age, gender, and socioeconomic status.

New medication gives mice bigger muscles
Researchers from Aarhus University, Denmark, have studied a new group of medicinal products which increase the muscle- and bone mass of mice over a few weeks.

Read More: Medication News and Medication Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.